This page is updated frequently with new Antagonist-related patent applications.
| Methods for diagnosing diseases associated with human signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
| Antibodies that bind novel pcsk9 variants|
The present invention provides novel polynucleotides encoding pcsk9b and pcsk9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides.
Bristol-myers Squibb Company
| Compositions and methods of use for therapeutic antibodies|
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
| Anti-cd40 antibodies and uses thereof|
The present invention encompasses antagonist anti-cd40 antibodies and antigen-binding portions thereof. Specifically, the invention relates to humanized anti-cd40 antibodies.
| Method and applying neuromuscular electrical stimulation|
A method and apparatus for applying neuromuscular electrical stimulation to an agonist/antagonist muscle pair to move a limb about a joint includes generating a first pattern of neuromuscular electrical stimulation pulses for output through a first channel to a first pair of electrodes and generating a second pattern of neuromuscular stimulation pulses for output through a second channel to a second pair of electrodes. The first pair of electrodes are attached to the agonist muscle of the agonist/antagonist muscle pair, and the second pair of electrodes are attached to the antagonist muscle.
Encore Medical Asset Corporation
| Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof|
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
| Composition and uses of galectin antagonists|
The present invention is directed to methods and compositions for augmenting treatment of cancers and other proliferative disorders. In particular embodiments, the invention combines the administration of an agent that inhibits the anti-apoptotic activity of galectin-3 (e.g., a “galectin-3 inhibitor”) so as to potentiate the toxicity of a chemotherapeutic agent.
La Jolla Pharmaceutical Company
| Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity|
Compounds of formula i, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.
| Aminoester derivatives|
Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratrory tract.. .
Chiesi Farmaceutici S.p.a.
| Aminoester derivatives|
Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.
Methods, agents and compositions for treatment of inflammatory conditions
The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g.
Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression.
Qaam Pharmaceuticals, Llc
Compositions and methods for reducing visual loss
The described invention provides a method for reducing visual loss and for treating one or more of adverse consequence of an eye disease, including abnormal intraocular pressure, retinal vascular disease, retinal ganglion cell death, or a combination thereof in order to reduce visual loss. The method entails providing a flowable particulate composition that contains a particulate formulation comprising a plurality of particles of uniform size distribution, a therapeutic amount of a therapeutic agent selected from a voltage-gated calcium channel antagonist, an endothelin receptor antagonist, or a combination thereof, and optionally an additional therapeutic agent, wherein the particles are of uniform size distribution, and wherein each particle comprises a matrix; and a pharmaceutically acceptable carrier.
Edge Therapeutics, Inc.
Solid pharmaceutical compositions of androgen receptor antagonists
The present invention belongs to the field of pharmaceutical industry and relates to a solid pharmaceutical composition comprising androgen receptor antagonists, e.g. Enzalutamide or arn-509, as well as to processes for preparing the same.
Lek Pharmaceuticals D.d.
Compositions for reducing hair loss and/or increasing hair regrowth
The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% of a 5α-reductase inhibitor or an androgen receptor antagonist, and 0.01% to 15% of a prostaglandin analogue. In one embodiment, the prostaglandin analogue is latanoprost.
Triple Hair, Inc.
Peripheral neural interface via nerve regeneration to distal tissues
At least partial function of a human limb is restored by surgically removing at least a portion of an injured or diseased human limb from a surgical site of an individual and transplanting a selected muscle into the remaining biological body of the individual, followed by contacting the transplanted selected muscle, or an associated nerve, with an electrode, to thereby control a device, such as a prosthetic limb, linked to the electrode. Simulating proprioceptive sensory feedback from a device includes mechanically linking at least one pair of agonist and antagonist muscles, wherein a nerve innervates each muscle, and supporting each pair with a support, whereby contraction of the agonist muscle of each pair will cause extension of the paired antagonist muscle.
Massachusetts Institute Of Technology
Increasing plant yield with bacterial/fungal combinations
A seed treated with a fungal/bacterial antagonist combination and a seed assembly comprising a seed and a fungal/bacterial antagonist combination. The fungal/bacterial antagonist combination comprises a trichoderma virens fungal antagonist and a bacillus amyloliquefaciens bacterial antagonist for controlling plant pathogens as a biocontrol agent, bio-pesticide or bio-fungicide.
Novozymes Bioag A/s
Cancer targets and uses thereof
Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“cat”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using cat.
Anti-il-6 antibodies for the treatment of anemia
The present invention is directed to therapeutic methods using il-6 antagonists such as anti-il-6 antibodies and fragments thereof having binding specificity for il-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.. .
Alderbio Holdings Llc
Process for the preparation of cycloheptapyridine cgrp receptor antagonists
The disclosure generally relates to a process for the preparation of compounds of formula i, including synthetic intermediates which are useful in the process.. .
Bristol-myers Squibb Company
Continuous production of photo-sensitive glass bodies
A method for continuous production of photo-sensitive glass bodies, glass bodies, and structured glass articles are provided. The glass bodies include a glass having si4+, at least one crystal-agonist, at least one crystal-antagonist, and at least one pair of nucleating agents.
Sensitized, photo-sensitive glass and its production
A sensitized, photo-structurable glasses and methods for producing are provided. The glasses includes si4+, one or more crystal-agonist, one or more crystal-antagonist, and one or more pair of nucleating agents.
Method for producing photo-structurable glass bodies by a redrawing method
A method for production of a photo-structurable glass element is provided. The method includes the steps of: fixing a blank of photo-structurable glass at a first end; heating of a deformation zone of the blank; and drawing the blank.
System for muscle development based on eccentric, concentric and isometric contractions of agonistic and antagonistic muscles, reactive to the direction of the force
The device according to the invention particularly targets muscle development based on isometric, concentric and eccentric contractions, that can be adapted to all sports activities. The device according to the invention can take the form of structures allowing vertical, horizontal or rotary types of force, or a combination of said types.
This invention relates to new use of dual nk-1/nk-3 receptor antagonists or a pharmaceutically acceptable salt thereof in the treatment of sex-hormone dependent diseases.. .
Nerre Therapeutics Limited
Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis. .
Eisai R&d Management Co., Ltd.
Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition.. .
Alpharma Pharmaceuticals Llc
Methods and monitoring of treatment with a dll4 antagonist
Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. .
Oncomed Pharmaceuticals, Inc.
Gene signatures associated with sensitivity to mdm2 inhibitors
Gene signatures that are predictive of the sensitivity of a cancer or tumor to an mdm2i or an antagonist of the mdm2-p53 interaction. Differentially expressed genes in the provided gene signatures serve as biomarkers assessing the sensitivity of cancer and tumor samples to treatment or therapy with an mdm2i.
Daiichi Sankyo Company, Limited
Baff selective binding compounds and related methods
The present invention relates to peptide antagonists that bind with high specificity and affinity to b-lymphocyte stimulator (“baff”), thereby antagonizing baff receptor (“baff-r”) signaling. The invention more specifically relates to vnar single chain antibodies derived from nurse shark that bind to baff, baff antagonist compounds and compositions comprising a baff specific vnar binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo b cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete b cells, such as in autoimmune diseases including systemic lupus erythematosus (sle), rheumatoid arthritis (ra) or multiple sclerosis (ms), and in certain hematological cancers, including lymphomas, leukemias and myelomas..
Use of antagonists of the interaction between hiv gp120 and a4b7 integrin
Methods are provided for the treatment of a hiv infection. The methods can include administering to a subject with an hiv infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the hiv infection.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
Methods and compositions for modulation of olfml3 mediated angiogenesis
The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists..
Research Development Foundation
E-selectin antagonists modified by macrocycle formation to the galactose
Provided herein are glycomimetic e-selectin antagonist compounds of formula (i)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising at least one macrocycle created through the 2nd and 3rd positions on a galactose within the mimic.
Heterocyclic sulfonamide derivative and medicine comprising same
Wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof. The compound has a superior trpa1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving trpa1 antagonist and trpa1..
Targeting of interleukin-1 and -18 signaling in treatment of septic shock
The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody.
Vista antagonist and methods of use
The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of vista. The invention further contemplates therapeutic use of the vista antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist..
The Trustees Of Dartmouth College
Methods and compositions for modifying sensorial perception
Compounds and methods for modifying sensory perception associated with transient sensory receptors trpa1, trpv1, and trpa1v1. A method for screening compounds for modulation of trpa1, trpv1, and/or trpa1v1.
The Procter & Gamble Company
Vegf antagonist compositions and uses thereof
The invention provides compositions and methods for treating a disease or disorder associate with vascular endothelial growth factor (vegf). Specifically, the invention relates to an oligomerized vegf binding domain to provide vegf antagonism, and thereby treat diseases associated thereof..
Inhibition of il-17 production
The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (il-17) by t cells, using an antagonist of interleukin-23 (il-23). The invention further concerns the use of il-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of il-17.
Selectively substituted quinoline compounds
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (sle) and lupus nephritis.. .
Eisai R&d Management Co., Ltd.
Compounds of formula (i) are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.. .
Chiesi Farmaceutici S.p.a.
Methods for treating cancer with dll4 antagonists
The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a dll4 antagonist..
Oncomed Pharmaceuticals, Inc.
Neurokinin-1 receptor antagonists for use in a prevention of cancer
Particularly, subject matter of the present invention is a neurokinin-1 receptor antagonist according to the compounds of formula (i) or a tautomer thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt of a tautomer thereof for use in a method of preventing cancer. In a very specific embodiment the non-peptide antagonist fosaprepitant sir aprepitant is said neurokinin-1 receptor antagonist.
Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer
The invention is directed to the use of retinoid x receptor-gamma (rxr-gamma) agonists and retinoid x receptor-alpha (rxr-alpha) antagonists in treatment of cancer.. .
St. Jude Children's Research Hospital, Inc.
Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
The present invention teaches methods for treating a variety of neurodegenerative conditions, including alzheimer's disease (ad) and idiopathic parkinson's disease (ipd), by utilizing adrenoceptor antagonists. Adrenoceptor antagonists that can be used include β-blockers, such as acebutolol, betaxolol, bisopropolol, bopindolol, carvedilol, metoprolol, oxprenolol, propranolol, and timolol..
Cedars-sinai Medical Center
Compositions and methods of treating a neurodegenerative disease
The present application relates to new uses of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.. .
Axovant Sciences Ltd.
Methods of treating a neurodegenerative disease
The present application relates to new uses of 5-ht6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-ht6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with, an acetylcholinesterase inhibitor for the treatment of a neurodegenerative disease.. .
Axovant Sciences, Ltd.
Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a nepi.. .
The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof. .
Motion analysis apparatus, analyzing motion, and motion analysis program
In order to estimate a movement command that a central nervous system is to select to implement a desired movement based on three feature amounts under the concepts of an antagonistic muscle ratio and an antagonistic muscle sum and based on a musculoskeletal model, a movement analysis apparatus includes: a myoelectric potential measurement unit to measure a myoelectric potential of a person who performs a movement; a movement measurement unit to measure a body movement; and a stiffness-ellipse calculation unit, an equilibrium-point calculation unit and a muscle synergy calculation unit to calculate, from measurement information obtained at the measurement units, feature amounts of a stiffness ellipse, an equilibrium point, and a muscle synergy that are base vectors describing the equilibrium point at an operating point based on a musculoskeletal model.. .